PTC Therapeutics
PTCT
180 hedge funds and large institutions have $2.2B invested in PTC Therapeutics in 2018 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 49 increasing their positions, 60 reducing their positions, and 27 closing their positions.
56% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 27
52% more capital invested
Capital invested by funds: $1.45B → $2.2B (+$753M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
8% more funds holding
Funds holding: 166 → 180 (+14)
0.86% more ownership
Funds ownership: 92.33% → 93.19% (+0.86%)
18% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 60
30% less call options, than puts
Call options by funds: $22.3M | Put options by funds: $31.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$109M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$75.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$60.5M |
| 4 |
O
OrbiMed
New York
|
+$52.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$52.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$66.7M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$52.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$35.2M |
| 4 |
RI
RTW Investments
New York
|
-$33M |
| 5 |
SCM
Scopia Capital Management
New York
|
-$28.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
201
Parallel Advisors
San Francisco,
California
| – | -$16K | -500 | Closed |
|
|
TRCT
202
Tower Research Capital (TRC)
New York
| – | -$15K | -442 | Closed |
|
203
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$10K | -286 | Closed |
|
204
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$7K | -200 | Closed |
|
|
IA
205
IFP Advisors
Tampa,
Florida
| – | -$1K | -15 | Closed |
|
|
BA
206
Ballew Advisors
Jackson,
Mississippi
| – | +$248 | +6 | New |
|
PTCT Hedge Fund Activity: Q3 2018 in Review
180 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2018, worth a combined $2.2B — up 52% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new PTCT positions and 27 closed out — a net gain of 15 holders — while 49 added to existing stakes and 60 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $109M. The largest seller was Avoro Capital Advisors, cutting an estimated $66.7M.
- 180 institutional investors held PTC Therapeutics (PTCT) as of Q3 2018, up from 166 in Q2 2018.
- Funds reported $2.2B of PTC Therapeutics stock for Q3 2018, up 52% quarter-over-quarter.
- 42 funds opened new PTC Therapeutics positions in Q3 2018 and 27 closed out, a net change of +15 holders.
- The largest PTC Therapeutics buyer in Q3 2018 was Franklin Resources, an estimated $109M added.
- The largest PTC Therapeutics seller in Q3 2018 was Avoro Capital Advisors, an estimated $66.7M sold.
Based on aggregated 13F filings for Q3 2018.